Depression is treatable, and most people improve with some combination of therapy, medication, lifestyle changes, or newer interventions. The challenge is that no single treatment works for everyone, and finding the right approach often takes some trial and adjustment. Here’s what the current evidence says about each option and what you can realistically expect from it.
Therapy: Two Proven Approaches
Cognitive behavioral therapy (CBT) and interpersonal therapy (IPT) are the two most studied forms of talk therapy for depression. CBT focuses on identifying and reshaping negative thought patterns that feed depressive cycles. IPT works on relationship problems and life transitions that may be driving or worsening your mood. Both are typically structured as weekly sessions over 12 to 20 weeks.
The largest comparison of these two therapies to date found no meaningful difference between them. Response rates, remission rates, and overall symptom reduction were essentially the same at the end of treatment and at long-term follow-up. That’s good news: it means you can choose whichever approach feels like a better fit for your situation. If your depression is tangled up with how you think about yourself and the world, CBT may feel more relevant. If it’s tied to grief, conflict, or isolation, IPT might click faster. What matters most is finding a therapist you trust and showing up consistently.
Antidepressant Medications
The most commonly prescribed antidepressants fall into two main classes. SSRIs (like sertraline and fluoxetine) work by increasing the availability of serotonin in the brain. SNRIs (like venlafaxine and duloxetine) do the same thing but also boost norepinephrine, another chemical messenger involved in mood and energy. For most people with moderate to severe depression, one of these is the first medication a doctor will suggest.
Neither class is clearly superior to the other overall, but individuals respond differently. If one doesn’t work or causes side effects you can’t tolerate, switching to another medication in the same class or trying the other class is standard practice. Common side effects include nausea in the first week or two, changes in sleep, weight fluctuation, and sexual side effects like reduced desire or difficulty with arousal. Many of the early side effects (especially nausea and jitteriness) fade within the first two weeks as your body adjusts.
How Quickly Medications Work
There’s a persistent belief that antidepressants take four to six weeks to “kick in,” but the reality is more nuanced. A meta-analysis of 76 trials found that 60% of overall improvement happens in the first two weeks, and about one-third of the total effect is already visible by the end of week one. Half of all people who ultimately respond to a six-week course respond within the first two weeks. So if you notice even a small shift early on, that’s a genuinely good sign. If nothing has changed after three or four weeks at an adequate dose, it’s reasonable to talk to your prescriber about adjusting.
Exercise as Treatment
Exercise is not just a vague “healthy habit” recommendation for depression. It has measurable, dose-dependent effects on symptoms. A systematic review of randomized controlled trials found a clear relationship between exercise volume and improvement: the minimum effective dose is roughly equivalent to 150 minutes per week of brisk walking, and the optimal response comes at a higher volume, closer to 45 to 60 minutes of moderate-intensity exercise five days a week.
Aerobic exercise (running, cycling, swimming) produced the strongest effect, followed closely by mind-body practices like yoga and tai chi, then mixed routines and resistance training. All four types outperformed inactive controls. The key takeaway: any movement helps, but consistency and moderate intensity matter more than the specific activity. If you’re currently sedentary, even starting with short daily walks can begin to shift your symptoms while you build toward a more robust routine.
Omega-3 Supplements
Fish oil has a modest but real effect on depression, with one important caveat: the type of omega-3 matters. A meta-analysis found that formulations containing at least 60% EPA (one of the two main omega-3 fatty acids) at doses up to 1 gram per day produced meaningful improvement in depressive symptoms. Formulations that were mostly DHA, the other main omega-3, did not show the same benefit.
If you’re considering a supplement, check the label for the EPA content specifically, not just total omega-3. Look for a product that delivers close to 1 gram of EPA daily. This isn’t a replacement for therapy or medication in moderate to severe depression, but it can be a useful addition, particularly if your diet is low in fatty fish.
Brain Stimulation Therapies
When therapy and medications haven’t worked well enough, brain stimulation techniques become an option. The two most established are electroconvulsive therapy (ECT) and transcranial magnetic stimulation (TMS).
ECT remains the most effective treatment for severe, treatment-resistant depression. It achieves a response rate of about 64% and a remission rate of 53%. It’s done under general anesthesia, typically two to three times per week for several weeks. The most common side effect is temporary memory disruption around the time of treatment. Modern ECT is quite different from its historical reputation, but it’s still reserved for cases where other treatments have failed or where rapid improvement is critical.
TMS is noninvasive. You sit in a chair while a magnetic coil delivers pulses to specific areas of the brain. High-frequency TMS produces a response rate of about 49% and remission in roughly 32% of patients. Sessions are typically daily over four to six weeks. There’s no anesthesia, no memory effects, and you can drive yourself home afterward. The most common side effect is a mild headache or scalp discomfort during the session. TMS is less effective than ECT on average, but its gentler side-effect profile makes it a reasonable step before considering ECT.
Newer and Faster-Acting Options
For people who need rapid relief, particularly those experiencing suicidal thoughts, a nasal spray called esketamine (brand name Spravato) is FDA-approved. It works on a completely different brain system than traditional antidepressants, targeting glutamate receptors rather than serotonin. The typical protocol starts at twice-weekly sessions for four weeks, then tapers to once weekly and eventually every other week. Each session is administered in a medical office, where you’re monitored for about two hours afterward because of potential side effects like dissociation, dizziness, and sedation.
Another newer option is a combination pill pairing dextromethorphan with bupropion (brand name Auvelity). It also works partly through glutamate pathways and showed statistically significant improvement over placebo as early as one week. This is notable because traditional antidepressants, while they can show early effects, often take longer to produce a clear separation from placebo. This medication is taken at home like a standard antidepressant, making it more accessible than esketamine for people whose depression hasn’t responded to first-line treatments.
Combining Treatments
Depression treatment works best when you don’t rely on a single intervention. The strongest evidence supports combining medication with therapy, which consistently outperforms either alone for moderate to severe depression. Adding regular exercise on top of that combination amplifies the effect further.
A practical approach looks something like this: start therapy and, if symptoms are moderate or severe, discuss medication with your doctor at the same time. Build in regular physical activity, even modest amounts at first. Consider an EPA-dominant omega-3 supplement as a low-risk addition. If the first medication doesn’t help after a few weeks at an adequate dose, switching or augmenting is the norm, not the exception. Most people try two or three approaches before landing on what works best for them.
Treatment-resistant depression, where two or more adequate medication trials haven’t worked, affects roughly one-third of people with the condition. If you’re in that group, TMS, esketamine, ECT, and newer medications like dextromethorphan-bupropion are all viable next steps. The important thing is not to interpret a failed treatment as a personal failure. It’s a signal to try a different mechanism, not to stop trying.